PMID- 35619175
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1757-4749 (Print)
IS  - 1757-4749 (Electronic)
IS  - 1757-4749 (Linking)
VI  - 14
IP  - 1
DP  - 2022 May 26
TI  - Adverse events of intestinal microbiota transplantation in randomized controlled 
      trials: a systematic review and meta-analysis.
PG  - 20
LID - 10.1186/s13099-022-00491-3 [doi]
LID - 20
AB  - BACKGROUND: Intestinal microbiota transplantation (IMT) has been recognized as an 
      effective treatment for recurrent Clostridium difficile infection (rCDI) and a 
      novel treatment option for other diseases. However, the safety of IMT in patients 
      has not been established. AIMS: This systematic review and meta-analysis was 
      conducted to assess the safety of IMT. METHODS: We systematically reviewed all 
      randomized controlled trials (RCTs) of IMT studies published up to 28 February 
      2021 using databases including PubMed, EMBASE and the Cochrane Library. Studies 
      were excluded if they did not report adverse events (AEs). Two authors 
      independently extracted the data. The relative risk (RR) of serious adverse 
      events (SAEs) and common adverse events (CAEs) were estimated separately, as were 
      predefined subgroups. Publication bias was evaluated by a funnel plot and Egger's 
      regression test. RESULTS: Among 978 reports, 99 full-text articles were screened, 
      and 20 articles were included for meta-analysis, involving 1132 patients (603 in 
      the IMT group and 529 in the control group). We found no significant difference 
      in the incidence of SAEs between the IMT group and the control group (RR = 1.36, 
      95% CI 0.56-3.31, P = 0.50). Of these 20 studies, 7 described the number of 
      patients with CAEs, involving 360 patients (195 in the IMT group and 166 in the 
      control group). An analysis of the eight studies revealed that the incidence of 
      CAEs was also not significantly increased in the IMT group compared with the 
      control group (RR = 1.06, 95% CI  0.91-1.23, P = 0.43). Subgroup analysis showed 
      that the incidence of CAEs was significantly different between subgroups of 
      delivery methods (P((CAE)) = 0.04), and the incidence of IMT-related SAEs and 
      CAEs was not significantly different in the other predefined subgroups. 
      CONCLUSION: Currently, IMT is widely used in many diseases, but its associated 
      AEs should not be ignored. To improve the safety of IMT, patients' conditions 
      should be fully evaluated before IMT, appropriate transplantation methods should 
      be selected, each operative step of faecal bacteria transplantation should be 
      strictly controlled, AE management mechanisms should be improved, and a close 
      follow-up system should be established.
CI  - (c) 2022. The Author(s).
FAU - Chen, Chong
AU  - Chen C
AD  - Department of Gastroenterology, The First Affiliated Hospital of Shenzhen 
      University, Shenzhen Second People's Hospital, Shenzhen, 518037, China.
FAU - Chen, Liyu
AU  - Chen L
AD  - Department of Gastroenterology, 923Th Hospital of PLA Joint Logistics Support 
      Force, Nanning, 530021, China.
FAU - Sun, Dayong
AU  - Sun D
AD  - Department of Gastroenterology, The First Affiliated Hospital of Shenzhen 
      University, Shenzhen Second People's Hospital, Shenzhen, 518037, China.
FAU - Li, Cailan
AU  - Li C
AD  - Department of Gastroenterology, 923Th Hospital of PLA Joint Logistics Support 
      Force, Nanning, 530021, China.
FAU - Xi, Shiheng
AU  - Xi S
AD  - Department of Gastroenterology, 923Th Hospital of PLA Joint Logistics Support 
      Force, Nanning, 530021, China.
FAU - Ding, Shihua
AU  - Ding S
AD  - Department of Gastroenterology, The First Affiliated Hospital of Shenzhen 
      University, Shenzhen Second People's Hospital, Shenzhen, 518037, China.
FAU - Luo, Rongrong
AU  - Luo R
AD  - Department of Gastroenterology, 923Th Hospital of PLA Joint Logistics Support 
      Force, Nanning, 530021, China.
FAU - Geng, Yan
AU  - Geng Y
AUID- ORCID: 0000-0002-5124-6444
AD  - Department of Gastroenterology, 923Th Hospital of PLA Joint Logistics Support 
      Force, Nanning, 530021, China. drggyn@163.com.
FAU - Bai, Yang
AU  - Bai Y
AD  - Guangdong Provincial Key Laboratory of Gastroenterology, Department of 
      Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, 
      510515, China. 13925001665@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220526
PL  - England
TA  - Gut Pathog
JT  - Gut pathogens
JID - 101474263
PMC - PMC9134705
OTO - NOTNLM
OT  - Adverse events
OT  - Intestinal microbiota transplantation
OT  - Meta-analysis
OT  - Randomized controlled trials
COIS- The authors have no conflicts of interest to declare.
EDAT- 2022/05/27 06:00
MHDA- 2022/05/27 06:01
PMCR- 2022/05/26
CRDT- 2022/05/26 23:50
PHST- 2021/05/29 00:00 [received]
PHST- 2022/04/11 00:00 [accepted]
PHST- 2022/05/26 23:50 [entrez]
PHST- 2022/05/27 06:00 [pubmed]
PHST- 2022/05/27 06:01 [medline]
PHST- 2022/05/26 00:00 [pmc-release]
AID - 10.1186/s13099-022-00491-3 [pii]
AID - 491 [pii]
AID - 10.1186/s13099-022-00491-3 [doi]
PST - epublish
SO  - Gut Pathog. 2022 May 26;14(1):20. doi: 10.1186/s13099-022-00491-3.